Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
Authors:
Open Access
- 10 March 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (3) , e006570
Abstract
Background: Immune checkpoint inhibitors (ICIs) have dramatically improved survival in patients with cancer but are often accompanied by severe immune-related adverse events (irAEs), which can sometimes be irreversible. Insulin-dependent diabetes is a rare, but life-altering irAE. Our purpose was to determine whether recurrent somatic or germline mutations are observed in patients who develop insulin-dependent diabetes as an irAE. Methods: We performed RNA and whole exome sequencing on tumors from 13 patients who developed diabetes due to ICI exposure (ICI-induced diabetes mellitus, ICI-DM) compared with control patients who did not develop diabetes. Results: In tumors from ICI-DM patients, we did not find differences in expression of conventional type 1 diabetes autoantigens, but we did observe significant overexpression of ORM1, PLG, and G6PC, all of which have been implicated in type 1 diabetes or are related to pancreas and islet cell function. Interestingly, we observed a missense mutation in NLRC5 in tumors of 9 of the 13 ICI-DM patients that was not observed in the control patients treated with the same drugs for the same cancers. Germline DNA from the ICI-DM patients was sequenced; all NLRC5 mutations were germline. The prevalence of NLRC5 germline variants was significantly greater than the general population (p=5.98×10−6). Although NLRC5 is implicated in development of type 1 diabetes, germline NLRC5 mutations were not found in public databases from patients with type 1 diabetes, suggesting a different mechanism of insulin-dependent diabetes in immunotherapy-treated patients with cancer. Conclusions: Validation of the NLRC5 mutation as a potential predictive biomarker is warranted, as it might improve patient selection for treatment regimens. Furthermore, this genetic alteration suggests potential mechanisms of islet cell destruction in the setting of checkpoint inhibitor therapy.Keywords
Funding Information
- National Institutes of Health (K12 CA215110, P50 CA121974, R01 CA216846, R01 CA227472, T32 CA193200-5)
This publication has 26 references indexed in Scilit:
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeNew England Journal of Medicine, 2016
- Immunogenetics of type 1 diabetes mellitusMolecular Aspects of Medicine, 2015
- Precipitation of Autoimmune Diabetes With Anti-PD-1 ImmunotherapyDiabetes Care, 2015
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- The Human Protein Atlas—a tool for pathologyThe Journal of Pathology, 2008
- Autoimmunizing Mechanisms in Thymoma and Thymus*Annals of the New York Academy of Sciences, 2008
- Pathological Roles Of Recoverin In Cancer-Associated Retinopathy2002
- Induction of Autoimmune Valvular Heart Disease by Recombinant Streptococcal M ProteinInfection and Immunity, 2001
- dbSNP: the NCBI database of genetic variationNucleic Acids Research, 2001